Arcturus Therapeutics Holdings (ARCT) Liabilities and Shareholders Equity (2018 - 2026)

Arcturus Therapeutics Holdings has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $245.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 26.03% year-over-year to $245.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.1 billion (down 22.78% YoY), and the FY2025 full-year result was $271.1 million, down 21.19% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $245.4 million, down from $271.1 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $470.9 million in Q1 2023, with the low at $245.4 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $363.2 million across 5 years, with a median of $344.1 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity slumped 32.43% — and 2023, when it surged 55.86%.
• Arcturus Therapeutics Holdings' Liabilities and Shareholders Equity stood at $450.4 million in 2022, then slipped by 4.66% to $429.4 million in 2023, then dropped by 19.87% to $344.1 million in 2024, then slipped by 21.19% to $271.1 million in 2025, then fell by 9.49% to $245.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $245.4 million (Q1 2026), $271.1 million (Q4 2025), and $282.3 million (Q3 2025), per Business Quant data.